Andrew John Hubert Gearing

Biocomm Square Pty Ltd. provides business development and licensing consulting services. The firm provides business development and licensing, corporate strategy, business planning, project management and portfolio review and technology assessment services. It also offers services like market analysis, competitive intelligence, scientific and commercial evaluation and assessment, in and out licensing strategy development, arrangement and implementation, research collaboration and alliances, biotechnology, biopharmaceuticals and cellular therapeutics services. The company was founded by Andrew John Hubert Gearing and Tsutomu Mori in 2007 and is headquartered in Clayton, Australia.

Genesis Research & Development Corp. Ltd. operates as a development stage company. Previously, it was a technology investment company that builds a broad therapeutic development platform targeting immune disorders and cancer and a novel single stranded gene silencing technology using the RNAi mechanism. The company was founded by James Douglas Watson in 1994 and is headquartered in Auckland, New Zealand.

Biocomm Services Pty Ltd. provides business development services for life sciences and biotechnology community. Its services include life sciences technology management and commercial development, licensing, market analysis, business planning, and seed financing. It serves the biotechnology industry. The company was founded in 2001 and is located in Melbourne, Australia

Cryptopharma Pty Ltd. develops novel anti-inflammatory therapeutic agents for the treatment of pulmonary diseases. It focuses on the development of CP92, a treatment of Cystic Fibrosis. The company was founded by Alastair George Stewart and John Lambert in October 2000 and is headquartered in Victoria, Australia.

Nexvet Australia Pty Ltd. operates as a global clinical-stage biopharmaceutical company that develops and distributes medicines for companion animals. The firm focuses on transforming the therapeutic market by developing and commercializing novel biologic therapies, including products derived from its PETization technology. PETization is designed to rapidly create monoclonal antibodies that are recognized as “self” by a patient’s immune system. The company was founded by Mark Heffernan, Christopher Nigel Brown and David Gearing in February 2010 and is headquartered in Melbourne, Australia.